Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
Date:11/10/2010

//www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning anticipated sales of our nutritional products and the timing thereof, the timing of anticipated shipment of our nutritional products, our expectations concerning conduct of the actual use study for our ibuprofen product, our expectations concerning regulatory approval of our pseudoephedrine product and the anticipated timing of such approval. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including lower than expected demand by national retailers for our nutritional products, our ability to conform to the sales planning cycles of the retailers targeted as potential customers for our nutritional products, constraints on our liquidity related to the greater working capital requirements of our nutritional business, unanticipated changes in the timing or amount of orders for our nutritional products, unanticipated problems or delays with our regulatory applications, unanticipated costs and expenses associated with our product development, clinical activities and regulatory review,  reductions in our royalty revenues, our ability to create and maintain partnerships or other relationships, the continuation of arrangements with our product development partners, customers and clinical project services providers, competition, government regulation and general economic conditions. For example, if we are not able to meet the timing and other expectations of the retailers we have targeted as potential customers of our nutritional products, we may not be able to generate revenue from sales of these
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
3. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
4. SCOLR Pharma, Inc. Licenses Dietary Supplements
5. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
6. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
7. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
8. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
9. Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition
10. Reportlinker Adds Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 4th Edition
11. Horizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 30, 2012  Today, in conjunction with its Investor Day being ... PRXL ) announced forward-looking earnings expectations for the ... for Fiscal Year 2012, and for Fiscal Year 2013.  ... quarter of Fiscal Year 2012 and for all of Fiscal ...
...  Stiefel, a GSK (NYSE: GSK ) company, ... agreement for the acquisition by Stiefel of exclusive development ... in all territories outside of China, Taiwan, Macao and ... development for the treatment of psoriasis and atopic dermatitis. ...
Cached Medicine Technology:PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 2PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 3PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day 4Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis 2
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research from ... apparently to blame for the surge. The researchers also found ... groups equally, with alarming increases in diabetes in blacks, Hispanics ... the April 15, 2014 issue of the Annals of ...
(Date:4/15/2014)... San Diego School of Medicine have identified a mechanism that ... disease and why the virus is able to persist in ... which infects an estimated 200 million people worldwide, attacks the ... cell,s innate ability to fight infection. It does this by ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... West Orange, NJ. April 10, 2014. John DeLuca, PhD, ... from Biogen Idec to study how persons with multiple ... "The Use of Actual Reality to Measure Everyday Life ... conduct this research. Dr. DeLuca is senior VP of ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... a troubled existence due to memory loss. The situation plummets ... patients live in The United Kingdom and most of them ... happen to such patients; lack of mental stimulation, social activity ... despair. ,The study, published in the journal Nature, ...
... do not pose a health hazard to workers in ... of 28,000 people, published ahead of print in// Occupational ... electromagnetic fields of 50 to 60 Hz has been ... breast cancers. ,The researchers used the health ...
... life in Rajasthan Monday as the mercury hovered between 40-45 ... ,The roads wore a deserted look with people preferring ... there would be no respite from the heat wave. ... of Rajasthan with the day temperatures four to six degrees ...
... for children, we have already been told. But now UK ... ,Professor Lawrie Challis, head of the government's committee on ... distance from the embedded antennas. ,Challis, a retired ... a desktop computer, the transmitter will be in the tower. ...
... Satraplatin, a chemotherapy drug has recently been tested ... Patients and found //to have significant improvement in ... University on Phase III trial on Satraplatin has ... for Improvement in Progression-Free Survival ...
... imagine when the cost of the error is three lives! ... in bad light following the irrevocable error committed by a ... explained how a weighing error committed by a worker during ... of three people in the Pacific Northwest, who consumed the ...
Cached Medicine News:Health News:Dementia – Worse With a Dull Life. Keep Busy, and Active to Improve Memory, Study Recommend 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 3Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 4Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: